Immune escape describes a critical event whereby tumor cells adopt an immunoresistant phenotype to escape adaptive surveillance. We show that expression of a pivotal negative regulator of T-cell function, B7-H1, correlates with PI(3) kinase activation in breast and prostate cancer patients. B7-H1-mediated immunoresistance can be attenuated by inhibitors of the PI(3) kinase pathway, and is dependent on S6K1-mediated translational regulation of B7-H1 protein. Breast and prostate carcinoma cells with activated PI(3) kinase lose the immunoresistant phenotype after treatment with B7-H1 siRNA. Conversely, breast and prostate carcinoma cells with minimal PI(3) kinase activation adopt an immunoresistant phenotype when engineered to overexpress B7-H1 protein. These observations describe a mechanism for immune escape from tumor dormancy in humans that relates to oncogenesis.
Cancer immunoediting describes the capacity of immunity to control and shape cancer development and progression (Bui and Schreiber, 2007) . Immunoediting is defined by three fundamental processes: (1) elimination, whereby immunosurveillance suppresses tumor growth, (2) equilibrium, whereby growth of transformed cancer cells is controlled by adaptive immunity and (3) escape, whereby cancer cell variants develop resistance to immune responses and grow into a clinically significant tumor. There is compelling experimental support for each of these steps: (1) immunodeficient mice develop more spontaneous tumors than wild-type mice (Shankaran et al., 2001) , (2) adaptive immunity maintains occult cancer in an equilibrium state in mice (Koebel et al., 2007) and (3) cancer cells from immunodeficient mice are more immunogenic than those from immunocompetent mice (Shankaran et al., 2001) . In humans, examples of immunoediting steps have been inferred from clinical anecdotes such as development of cancer in immunosuppressed patients after organ transplantation (Penn, 1996) . In these patients, cancer cells from the donor organ escape surveillance when adaptive immunity is attenuated in the transplant recipient. For immunocompetent patients, immune escape is likely more complex, involving a combination of oncogenic pathway activation and focal resistance of cancer cells to T-cell-mediated killing. To date, there have been no fundamental mechanisms identified that connect immunoresistance to oncogenesis in prevalent cancers known to express tumor-specific antigens, such as breast and prostate carcinoma.
Cancer cells can evade adaptive immunity by many methods including downregulation of MHC, expression of soluble factors and expression of membrane-bound proteins that prevent T-cell-mediated killing (Schartner et al., 2005; Liu et al., 2007; Parsa et al., 2007; Chang et al., 2008) . A recurring observation in many late-stage cancer vaccine trials has been that some patients experience a peripheral tumor-specific immune response without apparent clinical benefit (Powell et al., 2006; Johnson et al., 2007; Meyer et al., 2007; Slingluff et al., 2007) . This may be due to a specific immunoresistant phenotype that precludes T-cell-mediated killing of tumor target. We have reported earlier that transformed, pre-cancerous human astrocytes adopt an immunoresistant phenotype after the activation of the oncogenic PI(3)K pathway (Parsa et al., 2007) . The mechanism for this immunoresistance involves the protein B7-H1, a negative regulator of T-cell function (Dong et al., 2002; Mazanet and Hughes, 2002) . Normal tissues from mice and humans express B7-H1 transcript, but little or no B7-H1 protein (Wintterle et al., 2003) . In contrast, cancerous cells can express the B7-H1 protein, which induces apoptosis of activated T cells and impedes tumor-specific T-cell killing (Dong et al., 2002) . B7-H1 protein expression has been associated with a poor prognosis in multiple cancers, raising the possibility that immunoresistance confounds conventional therapies (Thompson et al., 2004 (Thompson et al., , 2006 Inman et al., 2007; Krambeck et al., 2007; Geng et al., 2008; Loos et al., 2008; Routh et al., 2008) . In this current study of breast and prostate cancer, we show that PI(3) kinase activation, either through PTEN loss or mutation in the gene, which encodes the catalytic subunit of PI(3)K (PIK3CA), is associated with an increase in B7-H1 protein-mediated immunoresistance.
To investigate the regulation of B7-H1 expression in breast and prostate carcininoma, we measured B7-H1 RNA and protein levels in a variety of cancer cell lines with known PI(3)K activation status. As the primary phosphatase of phosphatidylinositol (3,4,5)-trisphosphate, PTEN has a central role in modulating downstream effects of PI(3)K (Tamura et al., 1998; Dey et al., 2008) . Cell lines with loss of PTEN function, and activated PI(3)K, had significantly higher levels of B7-H1 protein, but similar levels of B7-H1 transcript relative to cell lines with functional PTEN (Figures 1a  and b) . The disparity in protein-to-transcript ratio in cells lacking PTEN function was due to polysomal recruitment of B7-H1 transcript (Figure 1c) . The amount of transcript in the polysomal fractions is Figure 1 Breast and prostate cancer cell lines lacking functional PTEN upregulate B7-H1 protein expression by increasing mTOR/S6 pathway-dependent translation. Breast and prostate cancer cell lines of either mutant (M) or wild-type (WT) PTEN expression were analyzed for expression levels of phospho-Akt, phospho-S6K and B7-H1 protein or B7-H1 mRNA by northern blot using targetspecific oligonucleotides (b). Total mRNA was fractionated using sucrose density fractionation as described earlier (Parsa et al., 2007) . Monosomal and polysomal mRNA fractions were probed for B7-H1 mRNA by northern blot (c). PTEN-deficient BT549 cells (d) or PC-3 cells (e) were treated with inhibitors to individual components of the mTOR signaling pathway (Wortmannin 100 mM, LY249002 100 mM, AKT inhibitor III 50 mM, rapamycin 100 ng) for 24 h prior to monosomal and polysomal mRNA fractionations. Fractions were subsequently analyzed for B7-H1 mRNA as in panel c. BT549 (f) or PC-3 (g) cells were treated with mTOR pathway inhibitors as in panel d, and levels of phospho-AKT, phospho-S6K, phospho-S6 (Thr 389) and B7-H1 proteins were examined by western blot (antibodies from Abcam, Cambridge, MA, USA). (h-i) PTEN WT cell lines overexpressing WT or kinase inactive S6K (kinase inactive: K100R) or eIF4E (kinase inactive: W73A) were assayed by western for total S6 and phospho-S6 (h) or B7-H1 (i) after transfection with either a nonspecific (scramble) siRNA or siRNA targeting S6 (Ambion, Cambridge, MA, USA). Results are from a representative experiment performed in triplicate. Error bars represent ±s.d.
proportional to transcript that is actively being translated. Accordingly, any shift to polysomal fraction or fractions is indicative of an increase in translation. To assess the involvement of the PI(3)K, Akt and mammalian Target of Rapamycin (mTOR) pathway in regulating the expression of B7-H1 protein, we inhibited each of these signaling mediators and measured transcript and protein levels. Treatment of PTEN-deficient breast and prostate carcinoma cell lines with inhibitors AktIII, LY294002, Wortmannin or rapamycin resulted in significant shifts of B7-H1 transcript from the polysomal compartment to the monosomal compartment, with an associated decrease in B7-H1 protein (Figures 1d-g ). Inhibition of any component of this signaling cascade had a similar effect on the quantity of polysomal mRNA and protein detected.
Activation of the PI(3)K, Akt and mTOR pathway increases translation through S6K1 activation and phosphorylation of eIF4E-binding proteins (Gingras et al., 1998) . Phosphorylation of ribosomal protein S6 by S6K1 facilitates translation of transcripts with 5 0 -TOP elements, and is most likely involved in regulating the translation of other transcripts. The eIF4E protein binds the 5 0 mRNA cap to initiate the assembly of the eIF4F complex, and in some cells can cross-activate S6K1 (Martin and Blenis, 2002) . Transfection of cells with constructs encoding S6K1 or eIF4E can simulate the effects of constitutive PI(3)K, Akt and mTOR pathway activity. To demonstrate this, we transfected wild-type or catalytically inactive mutant versions of eIF4E and S6K1 into breast and prostate carcinoma cell lines with wild-type PTEN. Transfection of both eIF4E and S6K1 resulted in an increase in B7-H1 protein expression, which was dependent on wild-type S6K activity, and this effect could be suppressed through S6K1 siRNA transfection (Figures 1h and i) . Collectively, these data suggest that loss of PTEN function promotes increased B7-H1 protein expression through the activation of the PI(3)K, Akt and mTOR pathway, which is secondary to S6K1-dependent polysomal recruitment of the B7-H1 transcript.
These results demonstrate that in breast and prostate cancer cell lines, loss of PTEN function is associated with enhanced B7-H1 protein levels. To address the functional consequences of these findings, we measured T-cell apoptosis, T-cell proliferation and T-cell cytokine production after exposing activated T cells to breast and prostate carcinoma. A significant increase in T-cell apoptosis (Figure 2a) , decrease in T-cell proliferation ( Figure 2b ) and decrease in Th1 cytokine production ( Figure 2c) were noted when co-culturing T cells with breast and prostate carcinoma cells deficient in PTEN. Taken together, these data indicate that PTEN loss can mitigate pro-inflammatory T-cell responses while inducing apoptosis of activated lymphocytes. PTEN-deficient tumor cell lines significantly also increased the percentage of FoxP3-expressing T cells (Figure 2c ). These FoxP3 þ cells are CD4 þ and CD25 þ (data not shown), a phenotype consistent with regulatory T cells, a cell type that can effectively suppress effector T-cell function. Our observation is consistent with recent study demonstrating that B7-H1 interaction with its ligand can induce FoxP3 þ regulatory T cells . Increased frequency of regulatory T cells may also contribute to the observed inhibition of proinflammatory cytokine production and proliferation. In contrast, breast and prostate carcinoma cells with functional PTEN had minimal impact on T-cell function, consistent with the relatively low expression of B7-H1 protein. The induction of T-cell apoptosis by PTEN-deficient, B7-H1-positive breast and prostate carcinoma cells was reversible by treatment with inhibitors of the PI(3)K, Akt and mTOR pathway (Figures 2d and e) , whereas siRNA knockdown of PTEN in wild-type breast and prostate carcinoma cells increased apoptosis of activated T cells (Figure 2f) .
To further investigate the role of B7-H1 in the immunoresistant phenotype of PTEN-deficient cells, we treated PTEN-deficient breast and prostate carcinoma cells with B7-H1 siRNA (Figure 2g) , and with B7-H1-blocking antibody (Supplementary Figure 2d) , which increased T-cell survival. Transfection of breast and prostate carcinoma cells with a B7-H1 expression vector promoted an increase in T-cell apoptosis despite the presence of functional PTEN (Figure 2g ). Collectively, these results support the premise that activation of the PI(3)K, Akt and mTOR pathway in breast and prostate carcinoma cells results in an immunoresistant phenotype mediated in part by an increase in B7-H1 protein expression.
To underscore the clinical relevance of our in vitro findings, we examined B7-H1 protein expression in breast and prostate cancer tissue, which was stratified on the basis of PI(3)K activation status (Table 1) . In breast and prostate cancer patients, activation of this pathway occurs through the loss of tumor suppressor PTEN function, as well as mutation of the gene encoding the PI(3)K catalytic subunit p110alpha (the PIK3CA gene) (Miled et al., 2007) . The prevalence of these and other mutations that ultimately lead to S6 kinase activation, and B7-H1 protein translation, suggest that many breast and prostate cancer patients have tumors with an immunoresistant phenotype. In the tumor specimens from breast and prostate cancer patients examined in this study, we found a significant correlation between B7-H1 protein expression and PI(3)K activation (Figures 3b and f) . Activation of the PI(3)K pathway, either through PTEN loss or PIK3CA mutation, resulted in detectable levels of B7-H1 protein by immunohistochemistry, with an associated increase in phospho-AKT staining (Figures 3d and h ). In contrast, specimens without PI(3)K pathway activation had minimal or undetectable levels of B7-H1 protein (Figures 3a and e) and minimal phospho-AKT staining (Figures 3c and g ).
Collectively, our data reveal an association between activation of an oncogenic pathway and immune escape in human breast and prostate carcinoma, supporting the concept of immunoediting in humans. After an oncogenic event resulting in the loss of PTEN function, it is possible that these cells persist, avoiding immune detection in part through B7-H1-mediated apoptosis of tumor-infiltrating Our data are consistent with recent study in this field highlighting the association of B7 family members with the progression of prostate cancer (Roth et al., 2007; Zang et al., 2007; Baleeiro and Barbuto, 2008; Siva et al., 2008) , suggesting that these tumors escape immune recognition in part by impairing T-cell effector function. These patients may therefore be resistant to currently used T-cell-mediated immunotherapies, including peptide (Meyer et al., 2007; Slingluff et al., 2007) -or antibody (Small et al., 2007) -based vaccines. Currently, the selection of patients for immunotherapy protocols does not take into account the immunoresistant phenotype of a tumor, with emphasis placed instead on criteria such as antigen expression and histology. Immunoresistance of tumors has been well documented in breast and prostate cancer systems (reviewed in (Mittendorf et al., 2007; Slovin, 2008) ), indicating a need for consideration of proteins that can modulate antitumor immunity. We propose that the observed association of PTEN loss and/or activation of PI(3)K, with the increase in B7-H1 expression and the resulting effects on T-cell function can further contribute to the failure of adaptive immunotherapies in some breast and prostate cancer patients. Accordingly, the data that we describe here, correlating PI(3)K activation with B7-H1 expression and immunoresistance, may be particularly important to investigators evaluating the results of completed immunotherapy trials. Representative histology slides are shown. (a) PI(3)K low-activity breast carcinoma shows minimal to no staining with B7-H1-specific antibody, (b) PI(3)K high-activity breast carcinoma shows positive staining, (c) PI(3)K low-activity breast carcinoma shows minimal to no staining with phopsho-AKT-specific antibody (d) B7-H1-positive breast carcinoma sample shows positive staining for phospho-AKT. (e) PI(3)K low-activity prostate carcinoma shows minimal to no staining with B7-H1-specific antibody, (f) PI(3)K high-activity prostate carcinoma shows positive staining, (g) PI(3)K low-activity prostate carcinoma shows minimal to no staining with phopsho-AKT-specific antibody, (h) B7-H1-positive prostate carcinoma sample shows positive staining for phospho-AKT.
